Arbutus Biopharma Corporation announced promising data from a late-breaker poster presentation at the EASL Congress 2025, revealing that its treatment combining imdusiran, a RNAi therapeutic, with VTP ...

Multiple abstracts accepted featuring imdusiran clinical data – highlighting progress toward a potential functional cure for chronic hepatitis B ...

(Reuters) -Arbutus Biopharma on Tuesday sued U.S. drugmaker Pfizer Inc and its German partner BioNTech SE in a New Jersey district court, claiming their mRNA COVID-19 vaccines infringe five of Arbutus ...

To get a sense of who is truly in control of Arbutus Biopharma Corporation (NASDAQ:ABUS), it is important to understand the ownership structure of the business. The group holding the most number of ...

With hepatitis C virus starting to look like a conquered foe, attention is turning to the fight against chronic hepatitis B virus (HBV), and Vivek Ramaswamy’s Roivant has just put another sizable ...

Roivant Sciences and Moderna Therapeutics, two of the most highly-funded and controversial companies in the biotechnology world, are headed for a collision course over medical technology. On Monday, ...

Arbutus Biopharma had made no secret of its plans to step up its work on imdusiran. Now, the company has regained the China rights to the potential functional cure for hepatitis B. China-based Qilu ...

Moderna stock fell 11% on Wednesday after the vaccine maker lost a patent fight against Arbutus Biopharma. Arbutus jumped 103% following the ruling as it could lead to royalty payments from Moderna.

It’s a David-and-Goliath fight between two unprofitable startups. Moderna Therapeutics is valued by its private investors at $5 billion, as it promises to create a new kind of medicine that will turn ...